الفهرس 
ACKNOWLEDGMENTOnly 14 pages are availabe for public view
 |  | from | 79 |  |  |
| | | from | 79 | | |
Abstract
HCV infection is a global health care problem with more than 170 million people infected worldwide. The pool of HCV infection is ultimately ends with cirrhosis and the subsequent life-threatening complications.
This prospective hospital based study included three sets of patients with approved HCV patients participating in the national program for treatment of HCV in Egypt:
a) Sofosbuvir-Simiprevir combination include 160 patients.
b) Sofosbuvir-Daclatasvir combination include 340 patients.
c) Sofosbuvir-ledipasvir combination include 90 patients.
We aimed to evaluate the response to different sofosbuvir based regimens in management of HCV infection in Egypt in terms of:
1. The percentage of patients achieved SVR, non-response or relapse (as defined in introduction).
2. Evaluation of the potential adverse events.
Five hundred and ninety patients with HCV infection was selected according the selection criteria determined by the National Committee for Control of Viral Hepatitis (NCCVH). Follow up HCV RNA quantitation was done at intervals: week 12, week 24 (from the start of therapy).
• At this study age range from 19-69 years old and the mean age was 45.34± 11.3 years. four hundred and fifty seven (77.5%) were males and 133 (22.5%) were females.
• SVR in Sofosbuvir-Simeprevir combination group was reported in 95.6% and it was reported in 97.4% in Sofosbuvir - Daclatasvir versus 97.8% in Sofosbuvir – ledipasvir combination.
• Minor adverse events was reported in 33.8% in Sofosbuvir-Simiprevir combination group and it was reported in 13.8%% in Sofosbuvir - Daclatasvir group versus 20% in Sofosbuvir – ledipasvir combination group which was mainly Headache, skin rash, sleep disturbance and gastric upset.